Published in J Clin Virol on January 01, 2011
Single molecule enzyme-linked immunosorbent assays: theoretical considerations. J Immunol Methods (2012) 1.01
Reduction of the HIV seroconversion window period and false positive rate by using ADVIA Centaur HIV antigen/antibody combo assay. Ann Lab Med (2013) 0.99
Cost savings associated with testing of antibodies, antigens, and nucleic acids for diagnosis of acute HIV infection. J Clin Microbiol (2012) 0.89
Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay. Med Microbiol Immunol (2012) 0.87
Detection of HIV-1 p24 at Attomole Level by Ultrasensitive ELISA with Thio-NAD Cycling. PLoS One (2015) 0.82
Real-life evaluation of a human immunodeficiency virus screening algorithm using a single combined p24 antigen-antibody assay. Eur J Clin Microbiol Infect Dis (2012) 0.82
Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests. PLoS One (2014) 0.79
Increased Sensitivity of HIV-1 p24 ELISA Using a Photochemical Signal Amplification System. J Acquir Immune Defic Syndr (2015) 0.78
Detection of HIV-1 p24 antigen in patients with varying degrees of viremia using an ELISA with a photochemical signal amplification system. Clin Chim Acta (2016) 0.77
Label-free single-cell protein quantification using a drop-based mix-and-read system. Sci Rep (2015) 0.76
Development of Monoclonal Antibodies against HIV-1 p24 Protein and Its Application in Colloidal Gold Immunochromatographic Assay for HIV-1 Detection. Biomed Res Int (2016) 0.75
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol (2009) 1.24
Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr (2010) 1.24
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS (2004) 1.22
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol (2006) 1.22
TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol (2004) 1.19
Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS (2005) 1.19
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol (2010) 1.16
Genotypic prediction of HIV-1 subtype D tropism. Retrovirology (2011) 1.16
NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5. Antivir Ther (2011) 1.16
Hepatitis E virus infections in blood donors, France. Emerg Infect Dis (2014) 1.15
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antivir Ther (2004) 1.14
Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. Emerg Infect Dis (2011) 1.13
Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol (2009) 1.13
Genotype 3 diversity and quantification of hepatitis E virus RNA. J Clin Microbiol (2012) 1.11
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother (2013) 1.10
Hepatitis C virus infection among pregnant women in Yaounde, Cameroon: prevalence, viremia, and genotypes. J Med Virol (2003) 1.09
Hepatitis E virus quasispecies and the outcome of acute hepatitis E in solid-organ transplant patients. J Virol (2012) 1.09
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother (2010) 1.09
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Am J Kidney Dis (2004) 1.09
Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant (2005) 1.08
Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism. Antimicrob Agents Chemother (2011) 1.07
High rate of hepatitis C virus infection and predominance of genotype 4 among elderly inhabitants of a remote village of the rain forest of South Cameroon. J Med Virol (2003) 1.06
New NS5B polymerase inhibitors for hepatitis C. Expert Opin Investig Drugs (2010) 1.06
Prolonged hepatitis E in an immunocompromised patient. J Gastroenterol Hepatol (2006) 1.06
A large nosocomial outbreak of hepatitis C virus infections at a hemodialysis center. Infect Control Hosp Epidemiol (2005) 1.06
Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. J Gen Virol (2005) 1.05
Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy. J Virol (2006) 1.05
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS (2009) 1.04
Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon. J Med Virol (2005) 1.04
Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol (2009) 1.04
Sensitivity of 8 CE (European Community)-approved rapid disposable tests for anti-HIV antibody detection during and after seroconversion. J Virol Methods (2009) 1.03
Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol (2009) 1.02
Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis (2010) 1.01
Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol (2003) 0.99
Low risk of mother-to-child transmission of hepatitis C virus in Yaounde, Cameroon: the ANRS 1262 study. Am J Trop Med Hyg (2005) 0.99
No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int (2009) 0.99
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One (2011) 0.98
Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. J Clin Virol (2012) 0.97
Genotypic prediction of HIV-1 CRF01-AE tropism. J Clin Microbiol (2012) 0.97
Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. J Antimicrob Chemother (2010) 0.95
Quantitation of human cytomegalovirus in recipients of solid organ transplants by real-time quantitative PCR and pp65 antigenemia. J Med Virol (2003) 0.95
An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PLoS One (2013) 0.95
Outcome of hepatitis E virus infection in patients with inflammatory arthritides treated with immunosuppressants: a French retrospective multicenter study. Medicine (Baltimore) (2015) 0.94
Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol (2013) 0.94
Hepatitis E virus infection in immunosuppressed patients: natural history and therapy. Semin Liver Dis (2013) 0.94
Comparison of 2 highly automated nucleic acid extraction systems for quantitation of human cytomegalovirus in whole blood. Diagn Microbiol Infect Dis (2011) 0.93
Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS (2007) 0.92
Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Arch (2007) 0.92
Intermittent detection of hepatitis C virus (HCV) in semen from men with human immunodeficiency virus type 1 (HIV-1) and HCV. J Med Virol (2003) 0.92
Risk of zoonotic transmission of HEV from rabbits. J Clin Virol (2013) 0.92
Screening of blood from potential organ and cornea donors for viruses. J Med Virol (2002) 0.92
Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS (2011) 0.91
Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients. Antimicrob Agents Chemother (2009) 0.91
Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation (2011) 0.91
Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dial Transplant (2010) 0.90
Genetic diversity of HCV genotype 2 strains in south western France. J Med Virol (2007) 0.90
Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. Am J Kidney Dis (2005) 0.90
Molecular evidence of patient-to-patient transmission of hepatitis E virus in a hematology ward. Clin Infect Dis (2009) 0.90
Influence of polyproline region and macro domain genetic heterogeneity on HEV persistence in immunocompromised patients. J Infect Dis (2013) 0.90
The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. BMC Infect Dis (2010) 0.89
Hepatitis E virus and the kidney in solid-organ transplant patients. Transplantation (2012) 0.89
Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-alpha therapy. Ann Intern Med (2010) 0.88
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. Transpl Int (2014) 0.88